tiprankstipranks
Advertisement
Advertisement

HK:1276 Stock Latest News

Jiangsu Hengrui Pharmaceuticals Publishes 2025 Audited Annual Results
Company AnnouncementsJiangsu Hengrui Pharmaceuticals Publishes 2025 Audited Annual Results
14d ago
1276
Jiangsu Hengrui Pharmaceuticals Proposes Final 2025 Dividend
PremiumCompany Announcements
Jiangsu Hengrui Pharmaceuticals Proposes Final 2025 Dividend
14d ago
1276
Hengrui Pharma Sets 2025 AGM to Approve Dividends and 20% Share Issuance Mandate
PremiumCompany Announcements
Hengrui Pharma Sets 2025 AGM to Approve Dividends and 20% Share Issuance Mandate
14d ago
1276
Jiangsu Hengrui Boosts Investment in Shanghai Regenelead via RMB750 Million Capital Increase
PremiumCompany Announcements
Jiangsu Hengrui Boosts Investment in Shanghai Regenelead via RMB750 Million Capital Increase
14d ago
1276
Hengrui Subsidiary Wins NMPA Nod for New Indication of Innovative HER2 Breast Cancer Drug
PremiumCompany Announcements
Hengrui Subsidiary Wins NMPA Nod for New Indication of Innovative HER2 Breast Cancer Drug
19d ago
1276
Hengrui Pharma Wins New China Approval for Hetrombopag Aplastic Anemia Use
PremiumCompany AnnouncementsHengrui Pharma Wins New China Approval for Hetrombopag Aplastic Anemia Use
26d ago
1276
Jiangsu Hengrui sets March 2026 board meeting to approve 2025 results
Premium
Company Announcements
Jiangsu Hengrui sets March 2026 board meeting to approve 2025 results
29d ago
1276
Jiangsu Hengrui Sets Tenth Board Session with Director Changes and New INED
Premium
Company Announcements
Jiangsu Hengrui Sets Tenth Board Session with Director Changes and New INED
1M ago
1276
Jiangsu Hengrui Pharma Delays Board Re-election, Extends Current Directors’ Terms
PremiumCompany Announcements
Jiangsu Hengrui Pharma Delays Board Re-election, Extends Current Directors’ Terms
2M ago
1276
Hengrui Subsidiary Wins NMPA Approval for Innovative Gastric Cancer Biologic
PremiumCompany Announcements
Hengrui Subsidiary Wins NMPA Approval for Innovative Gastric Cancer Biologic
3M ago
1276
Hengrui Pharma Shareholders Approve Amendments to Articles of Association
PremiumCompany Announcements
Hengrui Pharma Shareholders Approve Amendments to Articles of Association
3M ago
1276
Hengrui Pharma Signs 20-Year Licensing Deal and Service Pact with Connected Party Hansoh
PremiumCompany Announcements
Hengrui Pharma Signs 20-Year Licensing Deal and Service Pact with Connected Party Hansoh
3M ago
1276
Jiangsu Hengrui Pharmaceuticals to Hold Extraordinary Shareholders’ Meeting for Key Amendments
PremiumCompany AnnouncementsJiangsu Hengrui Pharmaceuticals to Hold Extraordinary Shareholders’ Meeting for Key Amendments
4M ago
1276
Jiangsu Hengrui Pharmaceuticals Proposes Amendments to Articles of Association
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals Proposes Amendments to Articles of Association
4M ago
1276
Jiangsu Hengrui Pharmaceuticals’ Drugs Added to National Reimbursement List
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals’ Drugs Added to National Reimbursement List
4M ago
1276
Jiangsu Hengrui Pharmaceuticals Appoints New Senior Vice President
PremiumCompany Announcements
Jiangsu Hengrui Pharmaceuticals Appoints New Senior Vice President
4M ago
1276
Jiangsu Hengrui Pharmaceuticals Reports Strong Q3 2025 Financial Results
PremiumCompany Announcements
Jiangsu Hengrui Pharmaceuticals Reports Strong Q3 2025 Financial Results
5M ago
1276
Jiangsu Hengrui Pharmaceuticals Gains Approval for Innovative Drug Combination
PremiumCompany Announcements
Jiangsu Hengrui Pharmaceuticals Gains Approval for Innovative Drug Combination
6M ago
1276
Jiangsu Hengrui Pharmaceuticals to Review Quarterly Results
PremiumCompany Announcements
Jiangsu Hengrui Pharmaceuticals to Review Quarterly Results
6M ago
1276
Jiangsu Hengrui Pharmaceuticals Licenses Innovative Cancer Drug to Glenmark Specialty
PremiumCompany AnnouncementsJiangsu Hengrui Pharmaceuticals Licenses Innovative Cancer Drug to Glenmark Specialty
7M ago
1276
Jiangsu Hengrui Pharmaceuticals Approves Resolutions at 2025 Shareholders’ Meeting
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals Approves Resolutions at 2025 Shareholders’ Meeting
7M ago
1276
Positive Buy Rating for Jiangsu Hengrui Pharmaceuticals Driven by Strategic Out-Licensing and Promising HRS-1893 Data
Premium
Ratings
Positive Buy Rating for Jiangsu Hengrui Pharmaceuticals Driven by Strategic Out-Licensing and Promising HRS-1893 Data
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >